Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845769 | 0.90 | CYP2C9 (0.48) | CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL2838530 | 0.89 | CYP2C9 (0.46) | CYP3A4CYP2C9KCNH2CYP2C19CYP2C8 | |
| SCHEMBL6120024 | 0.89 | ANO1 (0.48) | CYP3A4CYP2C8 | |
| SCHEMBL2403086 | 0.88 | CYP2C9 (0.46) | CYP3A4CYP2C9KCNH2CYP2C19CYP2C8 | |
| SCHEMBL2843678 | 0.88 | CYP2C9 (0.50) | CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL4791006 | 0.88 | CYP2C9 (0.45) | CYP3A4CYP2C9KCNH2CYP2C19CYP2C8 | |
| SCHEMBL2841611 | 0.87 | CYP2C9 (0.46) | CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL6120116 | 0.87 | CYP2C9 (0.44) | CYP3A4CYP2C9KCNH2CYP2C19CYP2C8 | |
| SCHEMBL4791003 | 0.86 | CYP2C9 (0.44) | CYP3A4CYP2C9KCNH2CYP2C19CYP2C8 | |
| SCHEMBL3542367 | 0.86 | CYP2C9 (0.46) | CYP3A4CYP2C9KCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2016154241-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2012067663-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | CYP3A4 437/4885CYP2C9 633/4885KCNH2 3902/4885 |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | POLI, POLR2E, POLR2H | CYP3A4 437/4885CYP2C9 633/4885KCNH2 3902/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | CYP3A4 437/4885CYP2C9 633/4885KCNH2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.